*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**廣東康華醫療集團股份有限公司**

**GUANGDONG KANGHUA HEALTHCARE GROUP CO., LTD.***

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3689)**

# CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF AUDIT COMMITTEE AND NOMINATION COMMITTEE

The Board hereby announces that:

(i) Dr. Chen Keji (陳可冀) has tendered his resignation as an independent non-executive Director and a member of each of audit committee of the Company (the "**Audit Committee**") and nomination committee of the Company (the "**Nomination Committee**"); and

(ii) Mr. Chen Weixiong (陳維雄) has been appointed as an independent non-executive Director and a member of each of Audit Committee and Nomination Committee.

The above changes will take effect from 30 June 2026.

The board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") of Guangdong Kanghua Healthcare Group Co., Ltd.* (廣東康華醫療集團股份有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces the following changes in composition of the Board.

## 1. RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND A MEMBER OF AUDIT COMMITTEE AND NOMINATION COMMITTEE

Dr. Chen Keji ("**Dr. Chen**") has tendered his resignation as an independent non-executive Director and a member of each of Audit Committee and Nomination Committee to devote more time to his other endeavours with effect from 30 June 2026. Dr. Chen has confirmed that he has no disagreement with the Board and he is not aware of any matter in relation to his resignation as an independent non-executive Director and a member of each of Audit Committee and Nomination Committee that should be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**"). The Board would like to take this opportunity to express its sincere gratitude to Dr. Chen for his valuable contribution to the Company during his tenure of service.

## 2. APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND A MEMBER OF AUDIT COMMITTEE AND NOMINATION COMMITTEE

The Board has convened a meeting on 30 June 2026, in accordance with the requirements of the Company Law of the People's Republic of China and articles of associations of the Company. The Board is pleased to announce that in view of Dr. Chen's resignation, Mr. Chen Weixiong ("**Mr. Chen**") has been appointed as an independent non-executive Director for an initial term commencing from 30 June 2026 ("**Effective Date**") until the conclusion of the next annual general meeting of the Company and shall be eligible for re-election. Mr. Chen also be appointed as a member of each of Audit Committee and Nomination Committee.

The Board, with the recommendation of the Nomination Committee, considers Mr. Chen satisfies the independence criteria under Rule 3.13 of the Hong Kong Listing Rules. The Nomination Committee believes that Mr. Chen has the required character, integrity and experience to continuously fulfil his role as an independent non-executive Director effectively. Accordingly, as recommended by the Nomination Committee, the Board has proposed that Mr. Chen be appointed as an independent non-executive Director.

The biographical details of Mr. Chen are set out below.

Mr. Chen Weixiong, formerly the Deputy Director of the Medical Insurance Department of Guangdong Provincial People's Hospital, is currently the Vice President of Jinshazhou Hospital of Guangzhou University of Chinese Medicine, a researcher, and an associate chief physician. He holds multiple professional degrees, including clinical medicine, health service management, and law. He currently serves as an expert for the National Healthcare Security Administration's selection of medical insurance drugs, an expert in the national expert database for large hospital inspections, a professional reviewer for the journal "China Medical Insurance", the Vice Chairman of the Medical Insurance Branch of the Chinese Society of Cardiovascular and Thoracic Anesthesiology, the Chairman of the Medical Insurance Refined Management Committee of the Guangdong Pharmaceutical Price Association, and the Vice Chairman of the Medical Insurance Working Committee of the Guangdong Medical Association, among other committees. He is also an expert reviewer for the Guangzhou Medical Insurance Bureau's GPO (Group Purchasing Organization), a core expert in the Guangzhou Medical Insurance Bureau's medical insurance payment system review organization, and an expert in the supervision of the Guangzhou Medical Security Fund. He is the chief editor of "Refined Management of Hospital Medical Insurance Based on Disease-Based (DIP/DRG) Value Payment" and "Catalogue of Corresponding Matching of Clinical Surgical Procedures and Medical Service Prices". He also participated in the writing (as associate editor) of the monographs "Hospital Management Strategies under Disease-Based Payment" and "Basic Theory and Application of Hospital Disease-Based and Disease Group Value Payment". He has presided over multiple medical insurance management research projects and published more than 20 medical and medical insurance management papers in journals and newspapers such as China Social Insurance, China Medical Insurance, Modern Hospital, and Health News.

Under the service contract with the Company, Mr. Chen will be entitled to a fixed director's fees of RMB120,000 per annum, which is determined by the Board and the remuneration committee of the Company with reference to the market rates for such position, and his qualifications, experience and responsibilities with the Company.

Save as disclosed above, as at the date of this announcement, Mr. Chen (i) does not hold any other positions with the Group, nor did he hold any directorship in any public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any other major appointment or professional qualification; (iii) does not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationship with any Directors, supervisors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company or its subsidiaries.

Save as disclosed above, as far as the Board is aware, there is no other matter in relation to the appointment of Mr. Chen that needs to be brought to the attention of the Shareholders or the Hong Kong Stock Exchange, nor any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

## 3. ACKNOWLEDGEMENT

The Board would like to express its sincere gratitude to Dr. Chen for his invaluable contribution to the Group during his term of service as an independent non-executive Director. The Board would also like to extend its warmest welcome to Mr. Chen on his new appointment to the Board.

By order of the Board
**Guangdong Kanghua Healthcare Group Co., Ltd.***
**WANG Junyang**
*Chairman*

Hong Kong, 30 June 2026

As at the date of this announcement, the Board comprises:

*Executive Directors:*
Mr. Wang Junyang *(Chairman)*
Mr. Chen Wangzhi *(Chief executive officer)*
Mr. Wong Wai Hung *(Vice chairman)*
Ms. Wang Aiqin

*Independent non-executive Directors:*
Ms. Lam Shiu Ling Cecilia
Mr. Chen Weixiong
Mr. Chan Sing Nun

*Non-executive Director:*
Mr. Jiang Xiwen

* *For identification purpose only*